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Abstract
Pleomorphic xanthoastrocytoma (PXA) is low-grade glial neoplasm principally affecting children and young adults.
Approximately 40% of PXA are reported to recur within 10 years of primary resection. Upon recurrence, patients receive
radiation therapy and conventional chemotherapeutics designed for high-grade gliomas. Genetic changes that can be
targeted by selective therapeutics have not been extensively evaluated in PXA and ancillary diagnostic tests to help
discriminate PXA from other pleomorphic and often more aggressive astrocytic malignancies are limited. In this study, we
apply the SNaPshot multiplexed targeted sequencing platform in the analysis of brain tumors to interrogate 60 genetic loci
that are frequently mutated in 15 cancer genes. In our analysis we detect BRAF V600E mutations in 12 of 20 (60%) WHO
grade II PXA, in 1 of 6 (17%) PXA with anaplasia and in 1 glioblastoma arising in a PXA. Phospho-ERK was detected in all
tumors independent of the BRAF mutation status. BRAF duplication was not detected in any of the PXA cases. BRAF V600E
mutations were identified in only 2 of 71 (2.8%) glioblastoma (GBM) analyzed, including 1 of 9 (11.1%) giant cell GBM
(gcGBM). The finding that BRAF V600E mutations are common in the majority of PXA has important therapeutic implications
and may help in differentiating less aggressive PXAs from lethal gcGBMs and GBMs.
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Introduction
Pleomorphic xanthoastrocytoma (PXA) is an uncommon low-
grade glial neoplasm of the central nervous system that most
frequently affects children and young adults [1–6]. The tumors
often arise in the temporal lobe and involve both the superficial
cortex and the overlying meninges [7–9]. During the clinical
evaluation of PXA resection specimens, the dense cellularity and
pleomorphism typical of PXA raises a differential diagnosis
including ganglioglioma and a range of high-grade malignancies
like glioblastoma (GBM), giant cell glioblastoma (gcGBM),
gliosarcoma or pleomorphic sarcoma [1,5]. The presence of
eosinophilic granular bodies and the compact, predominantly non-
infiltrating nature of PXA also can introduce pilocytic astrocytoma
into the differential diagnosis [5]. The histopathologic diagnosis of
PXA can often be accomplished readily when the histologic
findings are carefully considered in light of the clinical and
radiological features, although the diagnosis can be challenging
and confusion with other neoplasms can occur [10]. A
reproducible ancillary diagnostic marker for PXA would,
therefore, be of significant clinical use.
PXA are typically slow growing atp r e s e n t a t i o na n da sar e s u l t
patients commonly experience long-standing seizures. While the
p r o g n o s i si sr e l a t i v e l yf a v o r a b le, the recurrence rate following
resection is 30% within five years and about 40% within ten
years. The overall survival rate is 80% at five years and 70% at
ten years [9,11]. In its classic form, the histology of the tumors is
distinct with large pleomorphic giant cells demonstrating
xanthomatous change, a dense deposition of intercellular
reticulin and the presence of eosinophilic granular bodies
[12]. Anaplastic changes such as high mitotic activity and
necrosis are uncommon at initial presentation but become
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PXA typically involves surgical resection followed by radiolog-
ical monitoring [13]. Recurrent lesions or tumors that
demonstrate anaplastic features at primary resection are treated
with radiation [14] and chemotherapeutic protocols [7,10] that
are also used for anaplastic astrocytoma and glioblastoma. The
development of more selective targeted therapies for PXA and
the design of future clinical trials are dependent on an
understanding of the molecular genetic lesions that drive its
pathogenesis.
Identification of genetic lesions in PXA has been challenging for
a number of reasons. Most notably, the number of patients with
PXA is low even in large academic hospital centers resulting in a
paucity of cases for investigation. Since few tumor banks have
frozen PXA samples most analyses must be done on formalin-fixed
paraffin-embedded (PXA) tissue and robust technologies for
analyzing DNA from FFPE sources have only recently emerged
[15–17]. In addition, PXA cell lines are not available and animal
models have not been generated. To date, molecular genetic
analysis of PXA has been predominantly limited to TP53 revealing
mutations in 6% of cases (7 of 123) [18–21]. There is no
correlation between mutated TP53 and the presence of anaplastic
features. While amplifications of the EGFR, MDM2 or CDK4 loci
are absent [18], array CGH analysis demonstrated homozygous
loss of the 9p21.3 locus containing CDKN2A/CDKN2B in 6 of 10
cases [22].
Recently, multiplexed targeted sequencing platforms have been
developed that can be used to simultaneously investigate the
mutation status of multiple key cancer genes [15–17]. These assays
are capable of robustly identifying mutations in DNA derived from
FFPE samples and allow for the rapid identification of clinically
important and therapeutically tractable genetic mutations. In this
study, we use the SNaPshot mutation profiling assay to investigate
the mutation status of 15 cancer associated genes in 26 PXA and
71 GBM.
Materials and Methods
Tissue Samples and Pathology Review
Paraffin blocks from surgical resection specimens covering a
14-year period (1996–2010) were obtained from the archives of
Massachusetts General Hospital (MGH), Brigham and Women’s
Hospital (BWH) and Children’s Hospital Boston (CH) in
accordance with the regulations for excess tissue use stipulated
by the review boards of each institution. Cases were retrieved
for pathology review if the clinical diagnosis was gcGBM, PXA
or if the tumor was thought to display features suggestive of
PXA. Hematoxylin and eosin (H&E)-stained sections of all cases
were reviewed for the presence of pleomorphic cells, xantho-
matous cells, reticulin, eosinophilic granular bodies, inflamma-
tion, and calcifications, necrosis and microvascular prolifera-
tion. World Health Organization diagnostic criteria were used
for assigning histopathology diagnoses [2]. Six of the PXA II
samples in this study are also included in a separate study by
Schindler et al [23].
Ethics Statement
This study was conducted according to the principles outlined in
the Declaration of Helsinki. All work on human tissues was
conducted on excess archival human material from the Depart-
ments of Pathology at MGH, BWH and CH. The research study
was approved by the Institutional Review Board for Human
Research at MGH, BWH and CH as an excess tissue protocol and
the ethics committee specifically waived the need for consent. The
study was designed in light of recommendations from the STARD
(STAndards for the Reporting of Diagnostic accuracy studies)
statement. http://www.stard-statement.org/.
SNaPshot Sample Preparation
H&E-stained slides derived from representative surgical speci-
mens were evaluated for the presence of tumor. Available tumor
tissue was manually macro-dissected from serial 4-micron
unstained sections, or cored from the paraffin block using a 1.5-
mm dermal punch. Total nucleic acid was extracted from FFPE
tumor tissue using the FormaPure Kit (Agencourt Bioscience
Corporation, Beverly, MA) on a Beckman Coulter Biomek NX
P
workstation.
SNaPshot Genotyping
Our group has recently developed a tumor genotyping assay to
test tumor specimens prospectively and to guide clinical decision
making toward targeted therapies [15]. This clinical assay is based
on the SNaPshot method (Applied Biosystems) and consists of
multiplexed PCR and multiplexed single-base extension, followed
by capillary electrophoresis. The original tumor profiling panel
described by Dias-Santagata et al. [15], was expanded to include
four additional assays that test for hotspot mutations in the
isocitrate dehydrogenase genes 1 (IDH1) and 2 (IDH2), recently
shown to be frequently altered in gliomas [24]. The genotyping
analysis queried 60 commonly mutated loci in 15 cancer genes
(Table 1) testing for 140 previously described somatic mutations
(COSMIC database, v49 release). SNaPshot genotyping was
performed using previously described conditions [15]. Briefly,
genetic regions flanking the loci of interest were co-amplified using
eight multiplexed PCR primer pools and 60 ng of total nucleic
acid. PCR amplification (95uC68 min; 45 cycles of 95uC620 s,
58uC630 s, 72uC61 min) was followed by treatment with shrimp
alkaline phosphatase and exonuclease I (USB, Cleveland, OH).
Specific mutation loci were tested using 8 pools of extension
primers, each annealing immediately adjacent to the nucleotide
position of interest. A multiplexed single-base extension reaction
that adds a fluorescently labeled ddNTP to each locus-specific
probe was performed, using the ABI SNaPshot Multiplex Ready
Reaction Mix (96uC630 s; 25 cycles of 96uC610 s, 50uC65 s and
60uC630 s). Labeled extension products were resolved by
capillary electrophoresis on an automatic DNA sequencer (ABI
PRISM 3730 DNA Analyzer, Applied Biosystems) and data
analysis was performed using GeneMapper Analysis Software
version 4 (Applied Biosystems).
The following primers were used for targeted mutation analysis at
codon R132 in IDH1 (nucleotide positions c.394 and c.395) and at
the equivalent amino acid R172 in IDH2 (nucleotide positions c.514
and c.515): (PCR primers: IDH1 exon 4, 59-ACGTTGGA-
TGGGCTTGTGAGTGGATGGGTA-39 (forward) and 59-A C G -
TTGGATGGCAAAATCACATTATTGCCAAC-39 (reverse) and
IDH2 exon 4, 59- ACGTTGGATGAACATCCCACGCCTAG-
TCC-39 (forward), and 59- ACGTTGGATGCAGTGGATCCC-
CTCTCCAC-39 (reverse). Extension primers: IDH1.394 extR 59-
GACTGACTGGACTGACTGACTGACTGACTGGACTGAC-
TGACTGAGATCCCCATAAGCATGAC-39,I DH 1 .3 95ex tR5 9-
TGATCCCCATAAGCATGA-39, IDH2.514 extF 59-GACTG-
ACTGACTGACTGACTGACTGACTGGACTGACTGACTG-
ACTGACTGGACTGACTGACCCATCACCATTGGC-39 and
IDH2.515 extR 59- GACTGACTGACTGACTGACTGACT-
GACTGACTGACTGGACTGACTGACTGACTGACTGGAC-
TGACTGAGCCATGGGCGTGC-39). The primer sequences for
the other assays were previously described [15].
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Staining and Scoring
Clinical specimens that had been fixed in 10% buffered-
formalin and prepared as FFPE tissue blocks were used to generate
four-micron sections. The slides were stained with H&E. Serial
sections of the paraffin blocks were cut and these slides were used
for immunohistochemistry (IHC) as well as mutation analysis. For
IHC, tissue sections were deparaffinized and rehydrated through
xylene/graded alcohols. Endogenous peroxidase activity was
blocked with 3% hydrogen peroxide (15 min incubation) in
100% alcohol (1:1). Heat-induced antigen retrieval was carried out
with Dako Target Retrieval Solution, pH 6.0, and pressure cooker
heated (120+/22uC) for 30 seconds at 15+/25 psi. Sections were
stained for phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)
using a 1:500 dilution of rabbit monoclonal antibody (#4370:
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E)
from Cell Signaling Technology (Beverly, MA). The antibody was
optimized using SignalSlide
TM Phospho-p44/42 MAPK (Thr202/
Tyr204) IHC Controls from Cell Signaling (#8103) that consist of
paraffin-embedded NIH/3T3 cells that are either untreated or
PMA-treated. The antibody is reported to detect endogenous
levels of p44 and p42 MAP Kinase (Erk1 and Erk2) when
phosphorylated at residues Thr202 and Tyr204 of Erk1 and
(Thr185 and Tyr187 of Erk2), and singly phosphorylated at
Thr202. The antibody is reported not to cross-react with the
corresponding phosphorylated residues of either p38 MAP or
JNK/SAPK kinases. Application of the primary antibodies was
followed by a 30-minute incubation with Dako Labeled Polymer-
HRP anti-rabbit IgG secondary antibody, and visualized with 3,
39– diaminobenzidine (DAB) as a chromogen (Envision+ System)
with Mayer hematoxylin counterstaining. Grading of phospho-
p44/42 MAPK immunoreactivity was based on the following
semiquantitative approach: 0, no tumor cells demonstrating
staining; 1+, .0–25% of tumor cells reactive; 2+, .25%–50%
of tumor cells reactive; 3+, .50%–75% of tumor cells reactive; 4+,
.75% of cells reactive. Giant cell glioblastoma sections were
stained with a monoclonal antibody directed against p53 (clone
DO-1, Immunotech, Marseille, France) at a 1:1200 dilution using
similar conditions as described above for the phospho-p44/42
MAPK (Erk1/2). Reticulin staining was performed with Reticu-
lin/Nuclear Fast Red Stain Kit, Artisan
TM (DAKO, Carpinteria,
CA), according to the manufacturer’s recommendations.
Fluorescence In Situ Hybridization
Fluorescence in situ hybridization (FISH) was performed on four
micron tissue sections using the D7Z1 DNA Probe (chromosome 7
alpha satellite DNA) (Abbott Molecular) at 7p11.1-q11.1 and
homebrew probes (purchased from CHORI; www.chori.org)
RP11-767F15 and RP11-60F17 that map to 7q34. The RP11-
767F15 probe includes the 59 region of BRAF and the RP11-
60F17 probe includes the 39 region of BRAF. BRAF duplication
status was assessed in 50 tumor nuclei per case.
Statistical Analysis
Statistical Analysis consisted of Fisher’s exact test (association of
dichotomous factors), or t-test (comparison of means). Data
analysis was conducted using Prism 5.0b (GraphPad Software
Inc., San Diego, CA) and significance was defined as P,0.05.
Results
Glioma Cases Profiled with SNaPshot
To investigate the genetic changes underlying pleomorphic
xanthoastrocytomas, we identified relevant tumors that were
resected between 1996 and 2010 at Massachusetts General
Hospital, Brigham and Women’s Hospital, and Children’s
Hospital Boston. We retrieved cases that were thought to be
unequivocal grade II PXA during the clinical evaluation of the
surgical pathology specimens as well as tumors that demonstrated
most of the features of PXA and were thought to be ‘‘consistent
with PXA.’’ In addition, we identified cases of PXA with
anaplastic features (aPXA) such as necrosis and increased mitoses
as well as cases of giant cell glioblastoma (gcGBM, grade IV).
Representative images are illustrated in Figure 1. In all, we
retrieved 36 resection specimens of astrocytomas with marked
cellular pleomorphism from 35 patients, with one patient having
Table 1. SNaPshot tumor genotyping panel.
Gene
Amino acid - cDNA
residue Gene
Amino acid - cDNA
residue
APC R1114 - 3340C KRAS G12 - 34G
APC Q1338 - 4012C KRAS G12 - 35G
APC R1450 - 4348C KRAS G13 - 37G
APC T1556fs*
- 4666_4667insA
KRAS G13 - 38G
BRAF V600 - 1798G NOTCH1 L1575 - 4724T
BRAF V600 - 1799T NOTCH1 L1601 - 4802T
CTNNB1 D32 - 94G NRAS G12 - 34G
CTNNB1 D32 - 95A NRAS G12 - 35G
CTNNB1 S33 - 98C NRAS G13 - 37G
CTNNB1 G34 - 101G NRAS G13 - 38G
CTNNB1 S37 - 109T NRAS Q61 - 181C
CTNNB1 S37 - 110C NRAS Q61 - 182A
CTNNB1 T41 - 121A NRAS Q61 - 183A
CTNNB1 T41 - 122C PIK3CA R88 - 263G
CTNNB1 S45 - 133T PIK3CA E542 - 1624G
CTNNB1 S45 - 134C PIK3CA E545 - 1633G
EGFR G719 - 2155G PIK3CA Q546 - 1636C
EGFR T790 - 2369C PIK3CA Q546 - 1637A
EGFR L858 - 2573T PIK3CA H1047 - 3139C
EGFR E746_A750
- 2235_2249del
PIK3CA H1047 - 3140A
EGFR E746_A750
- 2236_2250del
PIK3CA G1049 - 3145G
FLT3 D835 - 2503G PTEN R130 - 388C
IDH1 R132 - 394C PTEN R173 - 517C
IDH1 R132 - 395G PTEN R233 - 697C
IDH2 R172- 514A PTEN K267fs*- 800delA
IDH2 R172 - 515G TP53 R175 - 524G
JAK2 V617 - 1849G TP53 G245 - 733G
KIT D816 - 2447A TP53 R248 - 742C
TP53 R248 - 743G
TP53 R273 - 817C
TP53 R273 - 818G
TP53 R306 - 916C
The panel tests 60 frequently mutated loci in 15 cancer genes. Because several
nucleotide variants have been described at each site, this assay can detect 140
previously described mutations according to the COSMIC database, v49 release
(http://www.sanger.ac.uk/genetics/CGP/cosmic/).
doi:10.1371/journal.pone.0017948.t001
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PXA with anaplastic features (BT 41). Thirty of the cases were
primary tumors and six were recurrences. Five of the six
recurrences had primary resections performed at an outside
hospital and the primary surgical specimen was not available for
genotyping. In total, we analyzed 20 cases of grade II PXA and six
cases of aPXA, (Table 2). We also analyzed nine gcGBM since this
variant of glioblastoma is commonly included in the differential
diagnosis of PXA. The age distribution of patients with grade II
PXAs was 7 years to 71.5 years with mean and median ages at
presentation of 25.8 years and 19.1 years, respectively. The age
distribution of patients at the time of aPXA resection was 29.3
years to 76.2 years with mean and median ages at presentation of
57.4 years and 54.3 years, respectively. The grade II PXAs
histologically fell into two general types: those that had
predominantly a distinct mesenchymal-like growth pattern with
fascicular and sometimes storiform growth pattern (PXA (m))
(Fig. 1A and B) and those that predominantly had a diffuse
fibrillary background (Fig. 1C and D). PXA (m) tumors were more
likely to demonstrate intercellular reticulin deposition. Interest-
Table 2. Clinical Data and Summary of Results.
Case # Hospital Gender
Age
(yrs)
Size
(cm) Side Location
Histology
Classification
SNaPshot
Result BRAF FISH pERK Reticulin
Specimen
Genotyped
BT06 CH F 7.0 3.4 Right Temporal PXA (m) BRAF V600E
(c.1799T.A)
No duplication 1 Present Recurrence
BT07 CH F 10.9 2.2 Left Temporal PXA No mutations No duplication 3 Absent Primary
BT19 MGH M 15.3 1 Right Temporal PXA (m) No mutations NA 4 Present Primary
BT20 MGH M 42.8 0.8 Left Occipital PXA* BRAF V600E
(c.1799T.A)
NA 4 Present Primary
BT21 MGH M 19.7 0.9 Left Temporal PXA BRAF V600E
(c.1799T.A)
No duplication 3 Focal Primary
BT22 MGH M 43.5 6.8 Left Frontal aPXA BRAF V600E
(c.1799T.A)
No duplication 4 Focal Recurrence
BT23 MGH F 47.1 1.2 Right Suprasellar PXA No mutations No duplication 2 Present Primary
BT24 MGH F 12.0 2.6 Right Temporal PXA (m) BRAF V600E
(c.1799T.A)
NA 4 Present Primary
BT25 BWH F 10.2 1.5 Left Frontal PXA No mutations No duplication 4 Present Primary
BT26 BWH M 71.5 2 Right Temporal PXA (m) BRAF V600E
(c.1799T.A)
No duplication 2 Present Primary
BT27 BWH M 37.9 6 Right Temporal PXA (m) BRAF V600E
(c.1799T.A)
No duplication 1 Present Primary
BT28 BWH M 18.8 NA Right Parietal PXA No mutations No duplication 2 Focal Recurrence
BT29 BWH M 45.7 0.6 Right Temporal PXA No mutations No duplication 4 Focal Primary
BT30 BWH M 29.3 3 Right Frontal aPXA No mutations No duplication 4 Present Primary
BT31 BWH M 29.1 NA Left Temporal PXA (m) BRAF V600E
(c.1799T.A)
No duplication 3 Present Recurrence
BT35 MGH M 24.5 1.9 Right Temporal PXA (m) BRAF V600E
(c.1799T.A)
NA 3 Present Primary
BT36 MGH F 76.2 5 Right Parietal aPXA No mutations NA 3 Focal Primary
BT38 CH F 18.7 1.2 Right Frontal PXA BRAF V600E
(c.1799T.A)
NA 2 Focal Recurrence
BT39 BWH M 18.6 2.4 Left Temporal PXA (m) BRAF V600E
(c.1799T.A)
No duplication 3 Focal Primary
BT41 BWH M 46.6 1.1 Right Temporal aPXA No mutations No duplication 4 Focal Recurrence
BT44 BWH M 86.8 NA Left Temporal aPXA No mutations NA 4 Absent Primary
BT46 CH F 19.3 3.8 Left Parietal/
Occipital
PXA No mutations No duplication 4 Present Primary
BT47 CH M 16.5 NA Right Temporal PXA (m) BRAF V600E
(c.1799T.A)
NA 1 Present Primary
BT48 CH F 16.3 1 Right Temporal PXA BRAF V600E
(c.1799T.A)
No duplication 2 Present Primary
BT49 BWH F 30.7 2.1 Left Temporal gcGBM arising in
PXA
BRAF V600E
(c.1799T.A)
NA 4 Focal Primary
BT52 MGH F 33.4 4 Right Temporal PXA No mutations NA 2 Focal Primary
BT56 BWH F 62.1 4.6 Right Frontal aPXA No mutations No duplication 4 Focal Primary
PXA – pleomorphic xanthoastrocytoma; PXA (m) – pleomorphic xanthoastrocytoma with mesenchymal-like growth pattern; aPXA – anaplastic pleomorphic
xanthoastrocytoma; NA – Not assessed.
doi:10.1371/journal.pone.0017948.t002
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growth originated in the temporal lobe. In contrast, only five of the
remaining 11 PXA cases (45%) were found in the temporal lobe,
with others located in frontal lobe (n=2), suprasellar region
(n=1), and in the parietal/occipital lobes (n=3). The mean age
for grade II PXA with prominent mesenchymal-like growth was
25.8 years, whereas the remaining grade II PXAs had a mean age
of 25.7 years.
SNaPshot Analysis Reveals that BRAF V600E Mutations
are Common in PXA
To characterize DNA mutations in this group of PXA tumors
we performed SNaPshot multiplexed genotyping (Figure 2). The
genotyping analysis queried 60 commonly mutated loci in 15
cancer genes (Table 1) testing for 140 previously described somatic
mutations (COSMIC database, v49 release). The BRAF V600E
mutation was identified in 12 of the 20 PXA (60%). The average
age of patients bearing the BRAF V600E-positive PXA was 26.2
years versus 25.1 years in those without the mutation. The average
tumor size at presentation for BRAF V600E-positive tumors was
2.2 cm compared to 2.0 cm for BRAF V600E-negative tumors. In
our cohort of 11 males and nine females with a PXA, 73% of
males with PXA (8 of 11) had a BRAF V600E mutation while only
44% of females with PXA (4 of 9) had a BRAF V600E mutation.
Despite BRAF V600E-positive PXA occurring more frequently in
males in our cohort, the association between tumor mutational
status and gender was not significant (p value 0.36). Interestingly,
the mutation was present in 8 of 9 PXA demonstrating prominent
mesenchymal-like growth pattern (PXA (m)), revealing a signifi-
cant association of BRAF V600E mutation with PXA (m) (p value
0.028). Of the remaining four BRAF V600E-positive PXA cases,
two were also present in the temporal lobe, one was present in the
frontal lobe and the remaining one originated in the occipital lobe
and displayed ganglion cell/neuronal differentiation (BT20). In all,
70% of the PXA originated in the temporal lobe and 83.3% of the
BRAF V600E-positive grade II PXAs were located in the temporal
lobe. Given the cohort size and the limited availability of follow up
data, correlative analysis regarding the prognostic significance of
the BRAF V600E mutation was not possible in grade II PXAs.
The BRAF V600E mutation was present in only one of the six
aPXA, in the single gcGBM arising from a PXA in our cohort and
in one of nine additional gcGBM (11%). The aPXA case bearing a
BRAF V600E mutation was a recurrence of a grade II PXA and
was located in the frontal lobe. The primary tumor for this
recurrence was not available for genotyping. The BRAF V600E-
positive gcGBM arising in a PXA was also located in the temporal
lobe. Neither of these two gcGBM specimens had amplification of
the EGFR locus.
BRAF V600E mutation has not been previously reported in
gcGBM but it has been reported to occur at low frequency in
glioblastoma and in one case of gliosarcoma. In total, BRAF
V600E mutation in standard glioblastomas has been reported in
approximately 1.7% of cases (5 of nearly 300 cases) [25–29]. In
line with this mutation frequency, review of 62 standard
glioblastoma cases that had undergone clinical testing at MGH
using SNaPshot mutation profiling identified only one case with a
BRAF V600E mutation (1.6%). Of note, SNaPshot clinical testing
of these 62 GBMs included the assays depicted in Table 1 except
for IDH2. Review of these GBM cases also revealed additional low
frequency mutations in cancer genes that have been previously
described to be altered in standard GBM (Table 3) including
mutations in IDH1 (3; 4.8%), KRAS (1; 1.6%), PIK3CA (4; 6.5%),
and TP53 (7; 11.3%) supporting the strength of using multiplexed
tumor genotyping to identify low frequency mutations, some of
which can be treated with targeted therapeutics. Also highlighting
the strengths of a multiplexed genotyping approach is the
observation that one of the mutations identified in IDH1
(c.394C.T) results in a R132C substitution that would not be
identified by IHC using an IDH1 R132H mutation specific
antibody.
One TP53 mutation (p.R248Q; c.743G.A) was found in a
gcGBM tumor sample but additional mutations profiled by the
SNaPshot system were absent in these gcGBM cases. Mutations in
the TP53 gene have been reported in 60–90% of gcGBM cases
[30–32]. Since the SNaPshot panels used in our experiments cover
less than 30% of the TP53 mutations that have been reported in
gcGBM (COSMIC database, v49 release), the odds dictate that we
would have detected a TP53 mutation in about 2 of the 9 cases in
this study. Support for the existence of TP53 mutations in many of
the gcGBMs analyzed in this study was provided by p53
immunohistochemistry which revealed increased p53 expression
in 7 of the 9 (78%) gcGBM.
Interestingly, none of the other mutations in the SNaPshot
panel that are commonly found in cancer were present in the
PXAs that were analyzed including those described above for
standard GBM. Of note, mutations at the most frequently affected
amino acid residues in the isocitrate dehydrogenase genes 1 (IDH1,
R132) and 2 (IDH2, R172) and TP53 (R175, G245, R248, R273
and R306) were not identified in any of PXA samples. In all, this
data shows the BRAF V600E mutation is common in PXA but is
Figure 1. Representative photomicrographs of tumors. A. H&E-
stained section of a pleomorphic xanthoastrocytoma (PXA, BT06)
demonstrating fascicular growth pattern and prominent intercellular
reticulin deposition (B) corresponding to PXA (m). C. H&E-stained
section of PXA (BT21) that demonstrates neither a fascicular growth
pattern nor prominent intercellular reticulin deposition (D). E. H&E-
stained section of a giant cell glioblastoma (gcGBM) arising from a PXA
(BT49) with marked pleomorphism and giant cells and multifocal
reticulin deposition (F).
doi:10.1371/journal.pone.0017948.g001
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gcGBM that enter the differential diagnosis of PXA.
Phospho-ERK Immunohistochemistry and BRAF FISH
Analysis
To address the functional consequences of BRAF V600E
mutations in PXA, we assessed MAPK pathway activation by
measuring levels of phospho-p44/42 MAPK (Erk1/2) by IHC.
While immunoblot analysis provides a quantitative method for
assessing differences in phosphorylation, access to only FFPE
and not frozen samples of this uncommon tumor permitted
analysis by the less quantitative method of IHC. Staining was
scored using a semiquantitive scoring system (0–4 scoring
system). Interestingly, the BRAF V600E mutation in grade II
PXA did not result in an overt increase in levels of phospho-
ERK for mutated tumors (mean score 2.4 for BRAF V600E-
positive Grade II PXA and 3.1 for BRAF V600E-negative
G r a d eI IP X A ;pv a l u e0 . 1 3 ) .R e p r e sentative images of staining
are displayed in Figure 3.
Since BRAF duplication has been identified as a mechanism for
activation of the MAPK pathway in pilocytic astrocytomas [33–
38] we investigated copy number alterations at the BRAF locus by
FISH. Results were obtained for seven of the 12 BRAF V600E-
positive grade II PXA, for six of the eight BRAF V600E-negative
grade II PXA and for three of the five aPXA lacking the BRAF
V600E mutation. While some tumors showed polysomy of
chromosome 7 (3–5 copies) in a portion of the tumor cells, none
of the tumors analyzed by FISH showed BRAF duplication
(Fig. 3G, H) suggesting that this mechanism does not account for
the activation of the MAPK pathway observed in BRAF V600E-
negative PXA.
Discussion
The BRAF V600E Mutation is Common in PXA
While BRAF V600E mutations have been described as a common
mutation in ganglioglioma (GG) by both our group and others
[16,39], the frequency of BRAF V600E mutation in other low-grade
gliomas has not been investigated in depth. An individual case with
BRAF V600E mutation has been reported for pilocytic astrocytoma
[16] and several diffuse astrocytomas (WHO grade II) have also been
Figure 2. Mutation profiling of pleomorphic xanthoastrocytoma and giant cell glioblastoma arising in a PXA reveals BRAF V600E
mutations. sections on the left illustrate SNaPshot genotyping and the sections on the right depict Sanger sequencing of BRAF exon 15 for the
same samples. The top panel shows genotyping data obtained with normal male genomic DNA (Promega, Madison, WI). The lower panels illustrate
BRAF V600E (c.1799T.A) mutation detection (arrows) in tumor DNA derived from formalin-fixed paraffin-embedded specimens of representative
examples of: PXA (BT21), anaplastic PXA (BT22) and gcGBM arising in a PXA (BT49). Assays: (1) EGFR 2235_49del R; (2) NRAS 38; (3) BRAF 1799; (4) NRAS
182; (5) PIK3CA 263; (6) TP53 742; (7) CTNNB1 95 and (8) CTNNB1 122.
doi:10.1371/journal.pone.0017948.g002
Table 3. Mutation analysis of GBM.
Gene Mutation No. of cases
BRAF p.V600E, c.1799T.A1
IDH1 p.R132C, c.394C.T1
p.R132H, c.395G.A2
KRAS p.G12A, c.35G.C1
PIK3CA p.R88Q, c.263G.A3
p.H1047R, c.3140A.G1
TP53 p.R175H, c.524G.A1
p.R248W, c.742 C.T2
p.R273C, c.817C.T2
p.R273H, c.818G.A1
p.R306*(STOP), c.916C.T1
SNaPshot clinical genotyping of 62 glioblastoma cases from MGH identified
cancer gene mutations that confer a favorable prognosis to the patients (IDH1)
or that activate pathways targeted by therapeutic agents under clinical
development (BRAF, KRAS and PIK3CA).
doi:10.1371/journal.pone.0017948.t003
Figure 3. Phospho-ERK (pERK) immunostaining and fluores-
cence in situ hybridization (FISH) for BRAF. Validation of the pERK
antibody using NIH/3T3 cells that are either untreated (A) or PMA-
treated (B). C. pERK IHC of BT06 PXA with a BRAF V600E mutation (IHC
semi-quantitative score 1). D. BT23 PXA without BRAF V600E mutation
(IHC semi-quantitative score of 2). E. BT24 PXA with a BRAF V600E
mutation (IHC semi-quantitative score 4). F. BT25 PXA without BRAF
V600E mutation (IHC semi-quantitative score of 4). G. BRAF FISH with
probes for CEP7 (centromeric control probe - aqua), 59BRAF (green) and
39BRAF (red). PXA BT29 demonstrating no duplication of the BRAF locus
and chromosome 7 disomy. H. PXA BT41, which is the recurrence of
BT29, did not have duplication of the BRAF locus but demonstrated
chromosome 7 polysomy.
doi:10.1371/journal.pone.0017948.g003
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The  identified with BRAF V600E mutation [16,39,40]. During the
preparation of this manuscript, individual cases of WHO grade II
PXA with BRAF V600E mutation have been reported with one
occurring in the temporal lobe of a 36-year-old woman [39], one in
the cerebral cortex of a six-year-old girl [41] and one in the temporal
lobe of a 16 year old boy with velocardiofacial syndrome [42].
Notably, we now identify the BRAF V600E mutation in approxi-
mately 60% of grade II PXA, a similar mutation rate as seen in
malignant melanoma [43]. Also of interest, is that a number of
common mutations found in some classes of human glial tumors are
absent in our PXA cohort, including mutations in IDH1 and IDH2
[24,44,45] and that BRAF is not duplicated in PXA. Also of note,
during the review process of this manuscript, a separate study was
published identifying BRAF V600E mutations in 66% of PXA [23],
consistent with the findings in our study.
There is variability in the histopathologic presentation of PXA.
Common features of PXA include xanthomatous change and marked
cellular pleomorphism, however, some tumors demonstrate fascicular
or storiform growth of spindle-type cells [1,7,46] while others are
characterized by a diffuse, glial/fibrillary pattern of growth [1]. Nearly
50% of the tumors in our series displayed a mesenchymal-like growth
pattern and were designated PXA (m) (Table 2). All of the PXA (m)
tumors originated in the temporal lobe and interestingly, in our series,
nearly all (89%) of these PXA (m) tumors harbored BRAF V600E
mutations, whereas the mutation was only present in 36% of the
remaining PXA. The gcGBM arising in a PXA which harbored a
BRAF V600E mutation in our series also arose from a PXA
demonstrating a mesenchymal-like growth pattern and was also
located in the temporal lobe. Analysis of more PXA cases will be
required to see whether the strong association holds between BRAF
V600E mutation and PXA (m). Nonetheless, our data seems to
support that the classification of PXA, as currently used, is molecularly
heterogeneous and may be composed of a group of BRAF V600E-
positive PXAs predominantly originating in the temporal lobe that
display pleomorphic giant cells, xanthomatous change, and fascicular
and storiform growth pattern. This group may be clinically and
molecularly distinct from the remaining PXA tumors.
Diagnostic Considerations
The diagnosis of PXA is traditionally based on examination of
H&E-stained sections and reticulin preparations as well as
integration of clinical and radiological information [1,2,5]. The
identification of BRAF V600E mutations as a common mutation
in PXA offers an ancillary diagnostic tool that can help
discriminate PXA from standard GBM and gcGBM as well as
pilocytic astrocytoma. Since a similar percentage of ganglioglioma
(GG) harbor BRAF V600E mutations (approximately 60%), the
BRAF V600E status will not help to discriminate PXA and GG.
While a more complete survey of other uncommon low-grade
gliomas is still required, it appears likely that the high frequency of
BRAF V600E mutations will be the hallmark of PXA and GG.
Interestingly, in addition to the strong clinicopathologic similarities
of PXA and GG, composite PXA-GG tumors are also observed,
albeit infrequently [47,48]. One of the cases in our study (BT 20)
demonstrates such mixed features and was found to carry a BRAF
V600E mutation. This molecular link between PXA and GG
further supports the clinicopathologic overlap between these
tumors and raises the possibility of a shared molecular pathogen-
esis/histogenesis.
Additional molecular tests can be used as part of a panel
including BRAF V600E analysis in the evaluation of PXA. The
absence of BRAF duplication in our PXA series can help
distinguish PXA from the 40% of non-cerebellar PAs and 80%
of cerebellar PAs [37] that have BRAF rearrangements. The
absence of IDH1 and IDH2 mutations in our PXA cohort suggests
that these mutations are rare or not present in PXA, a feature that
can help discriminate PXA from the 87.5% of diffuse glioma that
bear mutations in these gene [49]. Also, FISH or CISH for EGFR
can be of assistance since EGFR is amplified in 30–40% of GBM
[2]. The integrated molecular genetic evaluation of PXA can help
facilitate appropriate histologic classification.
Therapeutic Considerations
The activation of the MAPK pathway in PXA has significant
therapeutic implications as well. Moderate to high level expression
of phospho-ERK was observed by IHC in the majority of PXA
and aPXA suggesting that MAPK signaling is an important
component of PXA. These findings suggest that PXA may be
responsive to treatment with orally available BRAF kinase
inhibitors such as PLX-4032 [50] as well as by HSP90 inhibitors
which destabilize mutated BRAF [51,52]. BRAF V600E-positive
melanomas seem to be highly dependent on activation of the
MAPK pathway for proliferation and maintenance functions.
Preclinical testing in melanoma has demonstrated that PLX-4032
can inhibit the in vitro and in vivo proliferation of BRAF V600E
melanoma cell lines and clinical trials of PLX-4032 have shown
clinical responses in BRAF V600E melanoma with the extent of
response associated with the level of inhibition of phospho-ERK
[50,53–55]. These studies have provided the proof-of-principle for
the use of BRAF inhibitors in melanoma, and raise the possibility
of using targeted small molecule therapeutics like PLX-4032 in the
treatment of PXA and GG, particularly in the setting of
recurrence or in cases where noncytotoxic chemotherapy can
serve as an adjuvant treatment to permit resection of complex
lesions [56]. Most critical now will be to demonstrate sensitivity of
BRAF V600E-positive glioma cell lines and tumors to BRAF
targeted therapeutics. In addition it will be important to identify
and validate other pathways that contribute to the proliferation of
PXA and GG. Such studies could provide the rationale for
concurrently targeting additional pathways besides MAPK to
generate clinical responses and sustained remissions.
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